Pharmaceutical Microbiology West Coast
Pharmaceutical Microbiology West Coast
17th June to 18th June 2021,
San Diego, USA
SMi’s 4th Annual Conference
Pharmaceutical Microbiology West Coast
June 17th – 18th, 2021 | San Diego, USA
-------------------------------------------------------------------------
The pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods, revised industry regulation, enhanced knowledge of innovative therapies, novel testing methods, this industry is ever expanding.
Join industry experts to discuss the latest topics and pressing challenges within the industry. Network with industry professionals, discuss revisions in regulatory and guidance documents, explore data integrity considerations and approaches for conventional and rapid microbiology methods, discuss optimised environmental monitoring to best control contamination and gain insight into an industry perspective on alternative endotoxin testing methods and process automation, all contributing to better management of contamination in biopharmaceutical manufacturing.
source: http://www.smi-online.co.uk/pharmaceuticals/northamerica/conference/Microbiology-USA
If you have any questions about this news, please do not hesitate to contact us.
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE